![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
The present industry update covers the period 1–28 February 2019, with information sourced from company press releases, regulatory and patent agencies as well as scientific literature. Reports on new financing (Ocular Therapeutix™ Inc.; MA, USA) and licensing (Moberg Pharma; Bromma, Sweden) transactions as well as codevelopment agreements combining complimentary expertise (Biocorp; Issoire, France and AgaMatrix; Dillingen, Germany) remain strong. Also, the introduction of connected drug-delivery devices continues such as for insulin of the these two companies and the insulin pump by Tandem Diabetes Care (CA, USA) triggering the US FDA to generate new special controls regulatory frameworks for these novel product combinations. But also, the creative use of biological materials like the CARGOCYTE™ of Cytonus Therapeutics Inc. (CA, USA) or freeze-dried insulin functioning as its own injector (Novo Nordisk; Bagsværd, Denmark) demonstrate a plethora of combination products just entering the development pipeline.
Financial & competing interests disclosure
Oliver Steinbach is an employee of Royal Philips Electronics North America Corporation. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.